
    
      The primary objective is to determine whether secondary cytoreduction followed by
      chemotherapy is superior to chemotherapy alone in improving progression-free survival (PFS)
      and overall survival (OS) in patients with platinum-sensitive recurrent ovarian cancer
    
  